What is the projected market valuation of the Hospital-acquired Disease Testing Market by 2035?

The projected market valuation for the Hospital-acquired Disease Testing Market is expected to reach 8.42 USD Billion by 2035. Read More

What was the market valuation of the Hospital-acquired Disease Testing Market in 2024?

The overall market valuation of the Hospital-acquired Disease Testing Market was 4.129 USD Billion in 2024. Read More

What is the expected CAGR for the Hospital-acquired Disease Testing Market during the forecast period 2025 - 2035?

The expected CAGR for the Hospital-acquired Disease Testing Market during the forecast period 2025 - 2035 is 6.69%. Read More

Which testing methodologies are leading in the Hospital-acquired Disease Testing Market?

The leading testing methodologies include Polymerase Chain Reaction (PCR), Antigen Testing, and Serological Testing, with PCR projected to grow from 1.5 to 3.0 USD Billion. Read More

What types of diseases are primarily tested in the Hospital-acquired Disease Testing Market?

The primary types of diseases tested include Bacterial Infections, Viral Infections, Fungal Infections, and Parasitic Infections, with Bacterial Infections expected to grow from 1.5 to 3.1 USD Billion. Read More

What sample types are utilized in the Hospital-acquired Disease Testing Market?

Sample types utilized include Blood Samples, Urine Samples, Sputum Samples, and Swab Samples, with Blood Samples projected to increase from 1.5 to 3.1 USD Billion. Read More

What are the end-user segments in the Hospital-acquired Disease Testing Market?

End-user segments include Hospitals, Diagnostic Laboratories, Research Institutions, and Home Care Settings, with Hospitals expected to grow from 1.5 to 3.2 USD Billion. Read More

How does the market for viral infections compare to bacterial infections in terms of valuation?

The market for viral infections is projected to grow from 1.2 to 2.5 USD Billion, which is lower than the growth for bacterial infections from 1.5 to 3.1 USD Billion. Read More

What is the significance of the Hospital-acquired Disease Testing Market for healthcare providers?

The Hospital-acquired Disease Testing Market is crucial for healthcare providers as it enhances disease detection and management, thereby improving patient outcomes. Read More

Hospital acquired Disease Testing Market

Q: Who are the key players in the Hospital-acquired Disease Testing Market?

Key players in the market include Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers. Read More

ID: MRFR/HC/30168-HCR

128 Pages

Rahul Gotadki

Last Updated: May 15, 2026

Hospital-acquired Disease Testing Market Research Report: Size, Share, Trend Analysis By Testing Methodology (Polymerase Chain Reaction (PCR), Antigen Testing, Serological Testing, Nucleic Acid Testing), By Types of Disease (Bacterial Infections, Viral Infections, Fungal Infections, Parasitic Infections), By Sample Type (Blood Samples, Urine Samples, Sputum Samples, Swab Samples), By End Users (Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Hospital acquired Disease Testing Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.69%

2024 Market Size$ 4.13 Billion

2025 Market Size$ 4.41 Billion

2035 Market Size$ 8.42 Billion

Key Players

Thermo Fisher Scientific

Roche Diagnostics

Abbott Laboratories

Siemens Healthineers

Becton Dickinson and Company

bioMerieux

Trends

Technological Advancements in Testing
Increased Focus on Infection Control
Regulatory Pressures and Compliance

Opportunities

Growing Awareness of Patient Safety
Regulatory Compliance and Quality Standards
Technological Innovations in Diagnostic Tools

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Testing Methodology (USD Billion) | |
  1. 4.1.1 Polymerase Chain Reaction (PCR) | |
  2. 4.1.2 Antigen Testing | |
  3. 4.1.3 Serological Testing | |
  4. 4.1.4 Nucleic Acid Testing |
2. 4.2 Healthcare, BY Type of Disease (USD Billion) | |
  1. 4.2.1 Bacterial Infections | |
  2. 4.2.2 Viral Infections | |
  3. 4.2.3 Fungal Infections | |
  4. 4.2.4 Parasitic Infections |
3. 4.3 Healthcare, BY Sample Type (USD Billion) | |
  1. 4.3.1 Blood Samples | |
  2. 4.3.2 Urine Samples | |
  3. 4.3.3 Sputum Samples | |
  4. 4.3.4 Swab Samples |
4. 4.4 Healthcare, BY End User (USD Billion) | |
  1. 4.4.1 Hospitals | |
  2. 4.4.2 Diagnostic Laboratories | |
  3. 4.4.3 Research Institutions | |
  4. 4.4.4 Home Care Settings |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Thermo Fisher Scientific (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Roche Diagnostics (CH) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Abbott Laboratories (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Siemens Healthineers (DE) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Becton Dickinson and Company (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 bioMerieux (FR) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Hologic (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Cepheid (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Danaher Corporation (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TESTING METHODOLOGY |
7. 6.4 US MARKET ANALYSIS BY TYPE OF DISEASE |
8. 6.5 US MARKET ANALYSIS BY SAMPLE TYPE |
9. 6.6 US MARKET ANALYSIS BY END USER |
10. 6.7 CANADA MARKET ANALYSIS BY TESTING METHODOLOGY |
11. 6.8 CANADA MARKET ANALYSIS BY TYPE OF DISEASE |
12. 6.9 CANADA MARKET ANALYSIS BY SAMPLE TYPE |
13. 6.10 CANADA MARKET ANALYSIS BY END USER |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TESTING METHODOLOGY |
16. 6.13 GERMANY MARKET ANALYSIS BY TYPE OF DISEASE |
17. 6.14 GERMANY MARKET ANALYSIS BY SAMPLE TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY END USER |
19. 6.16 UK MARKET ANALYSIS BY TESTING METHODOLOGY |
20. 6.17 UK MARKET ANALYSIS BY TYPE OF DISEASE |
21. 6.18 UK MARKET ANALYSIS BY SAMPLE TYPE |
22. 6.19 UK MARKET ANALYSIS BY END USER |
23. 6.20 FRANCE MARKET ANALYSIS BY TESTING METHODOLOGY |
24. 6.21 FRANCE MARKET ANALYSIS BY TYPE OF DISEASE |
25. 6.22 FRANCE MARKET ANALYSIS BY SAMPLE TYPE |
26. 6.23 FRANCE MARKET ANALYSIS BY END USER |
27. 6.24 RUSSIA MARKET ANALYSIS BY TESTING METHODOLOGY |
28. 6.25 RUSSIA MARKET ANALYSIS BY TYPE OF DISEASE |
29. 6.26 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE |
30. 6.27 RUSSIA MARKET ANALYSIS BY END USER |
31. 6.28 ITALY MARKET ANALYSIS BY TESTING METHODOLOGY |
32. 6.29 ITALY MARKET ANALYSIS BY TYPE OF DISEASE |
33. 6.30 ITALY MARKET ANALYSIS BY SAMPLE TYPE |
34. 6.31 ITALY MARKET ANALYSIS BY END USER |
35. 6.32 SPAIN MARKET ANALYSIS BY TESTING METHODOLOGY |
36. 6.33 SPAIN MARKET ANALYSIS BY TYPE OF DISEASE |
37. 6.34 SPAIN MARKET ANALYSIS BY SAMPLE TYPE |
38. 6.35 SPAIN MARKET ANALYSIS BY END USER |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TESTING METHODOLOGY |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY TYPE OF DISEASE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TESTING METHODOLOGY |
45. 6.42 CHINA MARKET ANALYSIS BY TYPE OF DISEASE |
46. 6.43 CHINA MARKET ANALYSIS BY SAMPLE TYPE |
47. 6.44 CHINA MARKET ANALYSIS BY END USER |
48. 6.45 INDIA MARKET ANALYSIS BY TESTING METHODOLOGY |
49. 6.46 INDIA MARKET ANALYSIS BY TYPE OF DISEASE |
50. 6.47 INDIA MARKET ANALYSIS BY SAMPLE TYPE |
51. 6.48 INDIA MARKET ANALYSIS BY END USER |
52. 6.49 JAPAN MARKET ANALYSIS BY TESTING METHODOLOGY |
53. 6.50 JAPAN MARKET ANALYSIS BY TYPE OF DISEASE |
54. 6.51 JAPAN MARKET ANALYSIS BY SAMPLE TYPE |
55. 6.52 JAPAN MARKET ANALYSIS BY END USER |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TESTING METHODOLOGY |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY TYPE OF DISEASE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TESTING METHODOLOGY |
61. 6.58 MALAYSIA MARKET ANALYSIS BY TYPE OF DISEASE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE |
63. 6.60 MALAYSIA MARKET ANALYSIS BY END USER |
64. 6.61 THAILAND MARKET ANALYSIS BY TESTING METHODOLOGY |
65. 6.62 THAILAND MARKET ANALYSIS BY TYPE OF DISEASE |
66. 6.63 THAILAND MARKET ANALYSIS BY SAMPLE TYPE |
67. 6.64 THAILAND MARKET ANALYSIS BY END USER |
68. 6.65 INDONESIA MARKET ANALYSIS BY TESTING METHODOLOGY |
69. 6.66 INDONESIA MARKET ANALYSIS BY TYPE OF DISEASE |
70. 6.67 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE |
71. 6.68 INDONESIA MARKET ANALYSIS BY END USER |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TESTING METHODOLOGY |
73. 6.70 REST OF APAC MARKET ANALYSIS BY TYPE OF DISEASE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE |
75. 6.72 REST OF APAC MARKET ANALYSIS BY END USER |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TESTING METHODOLOGY |
78. 6.75 BRAZIL MARKET ANALYSIS BY TYPE OF DISEASE |
79. 6.76 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE |
80. 6.77 BRAZIL MARKET ANALYSIS BY END USER |
81. 6.78 MEXICO MARKET ANALYSIS BY TESTING METHODOLOGY |
82. 6.79 MEXICO MARKET ANALYSIS BY TYPE OF DISEASE |
83. 6.80 MEXICO MARKET ANALYSIS BY SAMPLE TYPE |
84. 6.81 MEXICO MARKET ANALYSIS BY END USER |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TESTING METHODOLOGY |
86. 6.83 ARGENTINA MARKET ANALYSIS BY TYPE OF DISEASE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE |
88. 6.85 ARGENTINA MARKET ANALYSIS BY END USER |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TESTING METHODOLOGY |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF DISEASE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TESTING METHODOLOGY |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF DISEASE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TESTING METHODOLOGY |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF DISEASE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TESTING METHODOLOGY |
103. 6.100 REST OF MEA MARKET ANALYSIS BY TYPE OF DISEASE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE |
105. 6.102 REST OF MEA MARKET ANALYSIS BY END USER |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TESTING METHODOLOGY, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TESTING METHODOLOGY, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY TYPE OF DISEASE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY TYPE OF DISEASE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY END USER, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY END USER, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY END USER, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY END USER, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY END USER, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY END USER, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY END USER, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY END USER, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY END USER, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY END USER, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY END USER, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY END USER, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY END USER, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY END USER, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY END USER, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY END USER, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY END USER, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY END USER, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY END USER, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY END USER, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY END USER, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY END USER, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY END USER, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY END USER, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY END USER, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY END USER, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY END USER, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TESTING METHODOLOGY, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY TYPE OF DISEASE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY END USER, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Hospital acquired Disease Testing Market Segmentation

Hospital acquired Disease Testing Market By Testing Methodology (USD Billion, 2025-2035)

Polymerase Chain Reaction (PCR)
Antigen Testing
Serological Testing
Nucleic Acid Testing

Hospital acquired Disease Testing Market By Type of Disease (USD Billion, 2025-2035)

Bacterial Infections
Viral Infections
Fungal Infections
Parasitic Infections

Hospital acquired Disease Testing Market By Sample Type (USD Billion, 2025-2035)

Blood Samples
Urine Samples
Sputum Samples
Swab Samples

Hospital acquired Disease Testing Market By End User (USD Billion, 2025-2035)

Hospitals
Diagnostic Laboratories
Research Institutions
Home Care Settings

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”